Generate:Biomedicines announced it is launching two Phase 3 trials for its lead TSLP-blocking antibody, marking a major clinical inflection for a company that integrates AI into therapeutic design. The move to large-scale registrational studies signals confidence in the preclinical and earlier clinical evidence and represents a milestone for AI-enabled biotech programs advancing to late‑stage development. The trials will assess efficacy and safety endpoints required for regulatory approval. Investors and potential partners will be watching enrollment speed and event rates as indicators of the platform’s translational value. The programs also test whether AI-guided discovery can reliably accelerate candidates from discovery to registrational trials.